drugset / Trial / NCT06969573

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

NCT06969573

Phase 2 Active not recruiting 20 enrolled University of Alberta
RandomizedCrossoverTriple-blindTreatment

Summary

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

Timeline

Start
2025-06-05
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 36 ug Inhaled
Subject Treprostinil Other / unclassified 78 ug Inhaled